Update on Tacrolimus in Patients With Interstitial Pneumonia Associated With Polymyositis or Dermatomyositis: 3-Year Postmarketing Surveillance Follow-Up in Japan.

IF 3.6 2区 医学 Q2 RHEUMATOLOGY Journal of Rheumatology Pub Date : 2024-09-15 DOI:10.3899/jrheum.2024-0379
Masataka Kuwana, Naoko Wakasugi, Tetsuji Hashida, Satoshi Uno, Takafumi Suda
{"title":"Update on Tacrolimus in Patients With Interstitial Pneumonia Associated With Polymyositis or Dermatomyositis: 3-Year Postmarketing Surveillance Follow-Up in Japan.","authors":"Masataka Kuwana, Naoko Wakasugi, Tetsuji Hashida, Satoshi Uno, Takafumi Suda","doi":"10.3899/jrheum.2024-0379","DOIUrl":null,"url":null,"abstract":"<p><p>In 2013, tacrolimus was approved in Japan for the treatment of interstitial lung disease (ILD) in patients with polymyositis (PM)/dermatomyositis (DM).<sup>1</sup> Subsequently, Kuwana et al<sup>2</sup> reported the 2-year interim prospective results of a postmarketing surveillance study, which found that tacrolimus-containing immunosuppressive regimens were well tolerated in patients with PM/DM-associated ILD.<sup>2</sup>.</p>","PeriodicalId":50064,"journal":{"name":"Journal of Rheumatology","volume":null,"pages":null},"PeriodicalIF":3.6000,"publicationDate":"2024-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Rheumatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3899/jrheum.2024-0379","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

In 2013, tacrolimus was approved in Japan for the treatment of interstitial lung disease (ILD) in patients with polymyositis (PM)/dermatomyositis (DM).1 Subsequently, Kuwana et al2 reported the 2-year interim prospective results of a postmarketing surveillance study, which found that tacrolimus-containing immunosuppressive regimens were well tolerated in patients with PM/DM-associated ILD.2.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
多发性肌炎或皮肌炎相关间质性肺炎患者使用他克莫司的最新进展:日本上市后监测随访 3 年。
2013 年,日本批准他克莫司用于治疗多发性肌炎(PM)/皮肌炎(DM)患者的间质性肺病(ILD)。1 随后,Kuwana 等人2 报告了一项上市后监测研究的两年中期前瞻性结果,研究发现,PM/DM 相关 ILD 患者对含他克莫司的免疫抑制方案耐受性良好。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of Rheumatology
Journal of Rheumatology 医学-风湿病学
CiteScore
6.50
自引率
5.10%
发文量
285
审稿时长
1 months
期刊介绍: The Journal of Rheumatology is a monthly international serial edited by Earl D. Silverman. The Journal features research articles on clinical subjects from scientists working in rheumatology and related fields, as well as proceedings of meetings as supplements to regular issues. Highlights of our 41 years serving Rheumatology include: groundbreaking and provocative editorials such as "Inverting the Pyramid," renowned Pediatric Rheumatology, proceedings of OMERACT and the Canadian Rheumatology Association, Cochrane Musculoskeletal Reviews, and supplements on emerging therapies.
期刊最新文献
Disparities in time to diagnosis of Radiographic Axial Spondyloarthritis. Potential Efficacy of Janus Kinase Inhibitors in the Treatment of a Patient With Coexisting Peripheral and Axial Spondyloarthritis and Ulcerative Colitis. Anifrolumab in Refractory Systemic Lupus Erythematosus: A Real-World, Multicenter Study. Scleroderma Renal Crisis: Clues From the Physical Exam. Systemic Sclerosis Sine Scleroderma: A Time of Reappraisal.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1